AsiaNet-Pakistan Premier Editorial Content and Press Release Distribution Service
Karachi, In a recent meeting held on August 22, 2023, in Karachi, the Board of Directors of GlaxoSmithKline Pakistan Limited shared their recommendations for the period. The key recommendations include:
Cash Dividend: NIL.
Additionally, the company unveiled its financial performance for the quarter and half-year ended June 30, 2023. The financial highlights are as follows:
Quarter Ended June 30, 2023:
Revenue from contracts with customers – net: Rs. 11,860,206,000
Cost of sales: Rs. (11,377,965,000)
Gross profit: Rs. 482,241,000
Selling, marketing, and distribution expenses: Rs. (1,207,141,000)
Administrative expenses: Rs. (430,793,000)
Other operating income (expenses): Rs. 27,340,000
Other Income: Rs. 493,890,000
Operating loss: Rs. (634,463,000)
Half Year Ended June 30, 2023:
Revenue from contracts with customers – net: Rs. 23,259,326,000
Cost of sales: Rs. (21,664,238,000)
Gross profit: Rs. 1,595,088,000
Selling, marketing, and distribution expenses: Rs. (2,268,713,000)
Administrative expenses: Rs. (869,609,000)
Other operating income (expenses): Rs. (31,811,000)
Other Income: Rs. 2,292,169,000
Operating profit: Rs. 717,124,000
The financial results showcase the company’s performance during the specified period. The presented data provides valuable insights into GlaxoSmithKline Pakistan Limited’s revenue, expenses, and earnings, indicating its overall financial health and trajectory.
The post GlaxoSmithKline Pakistan Limited Announces Board’s Recommendations and Financial Results for H1 2023 appeared first on Pakistan Company News.